UBS analyst Ashwani Verma lowered the firm’s price target on Legend Biotech (LEGN) to $54 from $60 and keeps a Buy rating on the shares. UBS continue to see upside to Legend Biotech stock, but the upside is based on modest growth in Q2, with an acceleration in the second half of 2025, the analyst tells investors in a research note. The stock may continue to be range-bound unless there is a material step-up in the revenue profile of Carvykti, UBS contends.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Promising Outlook for Legend Biotech’s CARVYKTI: Buy Rating Affirmed by Mitchell Kapoor
- Legend Biotech’s CAR T Cell Therapies See FDA REMS Removal and EMA Label Update
- Legend Biotech Concludes Successful 2025 Annual General Meeting
- Legend Biotech Unveils Updated Corporate Presentation Highlighting CAR-T Success
- Legend Biotech Appoints Peter Salovey as Lead Independent Director